Cerebral regional tissue oxygen saturation to guide oxygen delivery in preterm neonates during immediate transition after birth (COSGOD III)
An investigator-initiated, randomized, multi-center, multi-national, clinical trial on additional cerebral tissue oxygen saturation monitoring combined with defined treatment guidelines versus standard monitoring and treatment as usual in premature infants during immediate transition: Study protocol for a randomized controlled trial
Gerhard Pichler (Medical University Graz)
Sigrid Baumgartner (Medizinische Universität Wien)
Marlene Biermayr (Medical University of Innsbruck)
Eugene Dempsey (University College Cork)
Hans Fuchs (Albert-Ludwigs-Universität Freiburg)
Tom G. Goos (Erasmus MC, TU Delft - Medical Instruments & Bio-Inspired Technology)
Gianluca Lista (Ospedale dei Bambini “V.Buzzi”, Milano)
Laila Lorenz (University Children’s Hospital of Tübingen, Tubingen)
Lukasz Karpinski (Poznan University of Medical Sciences, Fredry)
undefined More Authors
More Info
expand_more
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.
Abstract
Background: Transition immediately after birth is a complex physiological process. The neonate has to establish sufficient ventilation to ensure significant changes from intra-uterine to extra-uterine circulation. If hypoxia or bradycardia or both occur, as commonly happens during immediate transition in preterm neonates, cerebral hypoxia-ischemia may cause perinatal brain injury. The primary objective of the COSGOD phase III trial is to investigate whether it is possible to increase survival without cerebral injury in preterm neonates of less than 32 weeks of gestation by targeting cerebral tissue oxygen saturation (crSO
2
) using specified clinical treatment guidelines during the immediate transition period after birth (the first 15 min) in addition to the routine monitoring of arterial oxygen saturation (SpO
2
) and heart rate (HR). Methods/Design: COSGOD III is an investigator-initiated, randomized, multi-center, multi-national, phase III clinical trial. Inclusion criteria are neonates of less than 32 weeks of gestation, decision to provide full life support, and parental informed consent. Exclusion criteria are severe congenital malformations of brain, heart, lung, or prenatal cerebral injury or a combination of these. The premature infants will be randomly assigned to study or control groups. Both groups will have a near-infrared spectroscopy (NIRS) device (left frontal), pulse oximeter (right palm/wrist), and electrocardiogram placed immediately after birth. In the study group, the crSO
2
, SpO
2
, and HR readings are visible, and the infant will receive treatment in accordance with defined treatment guidelines. In the control group, only SpO
2
and HR will be visible, and the infant will receive routine treatment. The intervention period will last for the first 15 min after birth during the immediate transition period and resuscitation. Thereafter, each neonate will be followed up for primary outcome to term date or discharge. The primary outcome is mortality or cerebral injury (or both) defined as any intra-ventricular bleeding or cystic periventricular leukomalacia (or both). Secondary outcomes are neonatal morbidities. Discussion: crSO
2
monitoring during immediate transition has been proven to be feasible and improve cerebral oxygenation during immediate transition. The additional monitoring of crSO
2
with dedicated interventions may improve outcome of preterm neonates as evidenced by increased survival without cerebral injury.
help_outline